The effects of antihypertensive therapy on haemostatic parameters

被引:24
作者
Ganotakis, ES
Papadakis, JA
Vrentzos, GE
Mikhailidis, DP
机构
[1] Royal Free Hosp, Dept Clin Biochem, Vasc Dis Prevent Clin, London NW3 2QG, England
[2] Univ Crete, Dept Internal Med, Iraklion, Greece
[3] UCL, Sch Med, London W1N 8AA, England
关键词
angiotensin; antihypertensive drugs; coagulation; endothelium; fibrinolysis; haemostasis; nitric oxide; platelets;
D O I
10.2174/1381612033453839
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is extensive trial-based evidence showing that antihypertensive drugs reduce the risk of vascular events (e.g. stroke and myocardial infarction) as well as target organ damage (e.g. left ventricular hypertrophy and microalbuminuria). However, some of these benefits appear to be, at least partially, independent of the extent of blood pressure (BP) lowering. It is also evident that in certain clinical situations some antihypertensive drugs are more effective than others. In this review we discuss the effects of antihypertensive drugs on the endothelium, platelets, fibrinolysis and coagulation. These properties may account for the observed BP-independent actions. Antihypertensive drugs exert multiple effects on the vascular endothelium. These include effects on nitric oxide (NO) and angiotensin II-mediated actions. Many BP lowering drugs can inhibit platelet activity, although the relevance of this property is unknown, especially if patients are also taking platelet inhibitors (e.g. aspirin). Antihypertensive drugs also influence Fibrinolysis and coagulation. These effects may be mediated by a variety of mechanisms, including altering insulin sensitivity. The haemostatic actions of anti hypertensive drugs deserve greater recognition and further investigation.
引用
收藏
页码:2445 / 2464
页数:20
相关论文
共 345 条
[1]   Pharmacological properties of combination therapies for hypertension [J].
Abernethy, DR .
AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (03) :S13-S16
[2]   VERAPAMIL, AN ANTAGONIST AT 5-HYDROXYTRYPTAMINE RECEPTORS OF HUMAN-BLOOD PLATELETS [J].
AFFOLTER, H ;
BURKARD, WP ;
PLETSCHER, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 108 (02) :157-162
[3]  
Ahaneku JE, 2000, PHARMACOL RES, V41, P75
[4]   Interactions of the renin-angiotensin system and alpha-1 adrenoceptors oil renal hemodynamics in healthy and acute renal failure rats: The role of nitric oxide [J].
Ajayi, AAL ;
Hercule, HC ;
Pamugo, J ;
Dixon, D ;
Oyekan, AO .
BLOOD PRESSURE, 2001, 10 (04) :238-246
[5]  
Akanji AO, 1998, CLIN CHIM ACTA, V274, P41
[6]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[7]  
Andersen AN, 1999, J INSECT CONSERV, V3, P61
[8]   Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) [J].
Anderson, TJ ;
Elstein, E ;
Haber, H ;
Charbonneau, F .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (01) :60-66
[9]   EFFECT OF PROPRANOLOL (LONG-ACTING) ON THE CIRCADIAN FLUCTUATION OF TISSUE-PLASMINOGEN ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 [J].
ANDREOTTI, F ;
KLUFT, C ;
DAVIES, GJ ;
HUISMAN, LGM ;
DEBART, ACW ;
MASERI, A .
AMERICAN JOURNAL OF CARDIOLOGY, 1991, 68 (13) :1295-1299
[10]   SEROTONIN PLAYS A MAJOR ROLE IN SERUM-INDUCED PHOSPHOLIPASE C-MEDIATED HYDROLYSIS OF PHOSPHOINOSITIDES AND DNA-SYNTHESIS IN VASCULAR SMOOTH-MUSCLE CELLS [J].
ARAKI, SI ;
KAWAHARA, Y ;
FUKUZAKI, H ;
TAKAI, Y .
ATHEROSCLEROSIS, 1990, 83 (01) :29-34